Please login to the form below
Human challenge study
This page shows the latest Human challenge study news and features for those working in and with pharma, biotech and healthcare.
Pfizer and viral infection specialist ReViral agree on $525m deal
Sisunatovir significantly reduced viral load in a phase 2 RSV human challenge study in healthy adults and is currently in phase 2 clinical development in infants.
Latest news
-
UK-based challenge study to re-expose healthy adults to COVID-19
Study will enrol participants aged 18-30 who have previously been infected with COVID-19. ... A new UK-based human challenge study will expose healthy volunteers who have previously had COVID-19 to the virus again, in a bid to gain a deeper understanding
-
UK to launch world-first COVID-19 human challenge study in the ‘next few weeks’
The world’s first COVID-19 human challenge study is set to begin in the UK within the next few weeks after receiving ethics approval, the government has announced. ... The COVID-19 human challenge study is part of a partnership between the UK’s
-
Sanofi will provide manufacturing support for Pfizer/BioNTech’s COVID-19 vaccine
Sanofi/GSK have now rescheduled their previous timeline for the vaccine, with a new plan to launch a phase 2b study next month. ... The phase 2b study will test an improved antigen formulation, after a recent challenge study in non-human primates showed
-
Merck ends its COVID-19 vaccine programme after disappointing early trial results
As a result, the two companies have delayed the programme, rescheduling their previous timeline for the vaccine with a new plan to launch a phase 2b study in February 2021. ... The phase 2b study will test an improved antigen formulation, after a recent
-
Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants
The phase 2b study will now test an improved antigen formulation, after a recent challenge study in non-human primates showed that this new formulation could protect against lung pathology. ... The improved antigen also lead to rapid viral clearance from
More from news
Approximately 3 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
Well-funded life sciences firms are making long-term progress – and their investors are too
Open Orphan’s unique approach to vaccine testing – conducted through a human challenge study in which subjects are exposed to the virus in question – will, they claim, help speed up the ... The company is also developing a SARS-CoV-2 human
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
-
Senior Medical Writer
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Italy accelerates the path towards digital therapeutics implementation
- AstraZeneca’s mild combination asthma reliever approved in UK
- Powering Rapid Cognitive Analysis with AI
- AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma
- Healthware Group report on depression care in Italy highlights need for digital therapeutics
- Masking the truth
- The speed of science and the pace of comms
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Ketchum appoints Conor Nash as global chief financial officer and chief operating officer
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
PMHub
Evoke Kyne
Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...
Latest intelligence
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
